Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance- associated protein 2 (rMrp2)

European Journal of Pharmaceutical Sciences

Volumn 26, Issue 5, 2005, Pages 405-413

  Ng, Chee ^a   Xiao, Yun De ^b   Lum, Bert L ^a   Han, Yong Hae ^c  

^a GENENTECH INC   (United States)

^b TARGACEPT INC   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Drug transport; Methotrexate; MRP; Multidrug resistance proteins; QSAR

Indexed keywords

GLUTATHIONE DERIVATIVE; METHOTREXATE; METHOTREXATE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 2; OCTANOL; WATER;

ARTICLE; BINDING AFFINITY; HYDROPHOBICITY; PARTITION CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; METHOTREXATE; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS;

EID: 27644478718     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2005.07.008     Document Type: Article

References (29)

1. S.F. Altschul, T.L. Madden, A.A. Schaffer, J. Zhang, Z. Zhang, W. Miller, and D.J. Lipman Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Nucleic Acids Res. 25 1997 3389 3402
2. B. Bannwarth, F. Pehourcq, T. Schaeverbeke, and J. Dehais Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis Clin. Pharmacokinet. 30 1996 194 210
3. S. Ekins, G. Bravi, S. Binkley, J.S. Gillespie, B.J. Ring, J.H. Wikel, and S.A. Wrighton Three- and four-dimensional quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors Pharmacogenetics 9 1999 477 489
4. S. Ekins, G. Bravi, S. Binkley, J.S. Gillespie, B.J. Ring, J.H. Wikel, and S.A. Wrighton Three- and four-dimensional quantitative structure-activity relationship analyses of cytochrome P-450 3A4 inhibitors J. Pharmacol. Exp. Ther. 290 1999 429 438
5. S. Ekins, G. Bravi, B.J. Ring, T.A. Gillespie, J.S. Gillespie, M. Vandenbranden, S.A. Wrighton, and J.H. Wikel Three-dimensional quantitative structure-activity relationship analyses of substrates for CYP2B6 J. Pharmacol. Exp. Ther. 288 1999 21 29
6. S. Ekins, G. Bravi, J.H. Wikel, and S.A. Wrighton Three-dimensional quantitative structure-activity relationship analysis of cytochrome P-450 3A4 substrates J. Pharmacol. Exp. Ther. 291 1999 424 433
7. S. Ekins, R.B. Kim, B.F. Leake, A.H. Dantzig, E.G. Schuetz, L.B. Lan, K. Yasuda, R.L. Shepard, M.A. Winter, J.D. Schuetz, J.H. Wikel, and S.A. Wrighton Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates Mol. Pharmacol. 61 2002 974 981
8. K.N. Faber, M. Muller, and P.L. Jansen Drug transport proteins in the liver Adv. Drug Deliv. Rev. 55 2003 107 124
9. J.P. Gallivan, and D.A. Dougherty Cation-π interactions in structural biology Proc. Natl. Acad. Sci. U.S.A. 96 1999 9459 9464
10. J. Gasteiger, and M. Marsili Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges Tetrahedron 36 1980 3219 3228
11. P. Geladi, and K. BR Partial least square regression: a tutorial Anal. Chem. Acta 185 1986 1 17
12. P.M. Gerk, and M. Vore Regulation of expression of the multidrug resistance-associated protein 2 (MRP2) and its role in drug disposition J. Pharmacol. Exp. Ther. 302 2002 407 415
13. Y.H. Han, Y. Kato, M. Haramura, M. Ohta, H. Matsuoka, and Y. Sugiyama Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2) Pharm. Res. 18 2001 579 586
14. S. Hirono, I. Nakagome, R. Imai, K. Maeda, H. Kusuhara, and Y. Sugiyama Estimation of the three-dimensional pharmacophore of ligands for rat multidrug-resistance-associated protein 2 using ligand-based drug design techniques Pharm. Res. 22 2005 260 269
15. J.H. Hooijberg, H.J. Broxterman, M. Kool, Y.G. Assaraf, G.J. Peters, P. Noordhuis, R.J. Scheper, P. Borst, H.M. Pinedo, and G. Jansen Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2 Cancer Res. 59 1999 2532 2535
16. K. Ito, C.J. Oleschuk, C. Westlake, M.Z. Vasa, R.G. Deeley, and S.P. Cole Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity J. Biol. Chem. 276 2001 38108 38114
17. J. Konig, A.T. Nies, Y. Cui, I. Leier, and D. Keppler Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance Biochim. Biophys. Acta 1461 1999 377 394
18. T. Konno, T. Ebihara, K. Hisaeda, T. Uchiumi, T. Nakamura, T. Shirakusa, M. Kuwano, and M. Wada Identification of domains participating in the substrate specificity and subcellular localization of the multidrug resistance proteins MRP1 and MRP2 J. Biol. Chem. 278 2003 22908 22917
19. W. Lee, and R.B. Kim Transporters and renal drug elimination Annu. Rev. Pharmacol. Toxicol. 44 2004 137 166
20. M. Masuda, Y. I'Izuka, M. Yamazaki, R. Nishigaki, Y. Kato, K. Ni'inuma, H. Suzuki, and Y. Sugiyama Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats Cancer Res. 57 1997 3506 3510
21. R.S. Obach, J.G. Baxter, T.E. Liston, B.M. Silber, B.C. Jones, F. MacIntyre, D.J. Rance, and P. Wastall The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data J. Pharmacol. Exp. Ther. 283 1997 46 58
22. H. Suzuki, and Y. Sugiyama Transporters for bile acids and organic anions W. Sadee G. Amidon Membrane Transporters as Drug Target 1999 Plenum Publishing New York 387 394
23. M. Trauner, and J.L. Boyer Bile salt transporters: molecular characterization, function and regulation Physiol. Rev. 83 2003 633 671
24. J.J. van Zanden, H.M. Wortelboer, S. Bijlsma, A. Punt, M. Usta, P.J. Bladeren, I.M. Rietjens, and N.H. Cnubben Quantitative structure-activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2 Biochem. Pharmacol. 69 2005 699 708
25. E.L. Volk, K.M. Farley, Y. Wu, F. Li, R.W. Robey, and E. Schneider Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance Cancer Res. 62 2002 5035 5040
26. E.L. Volk, and E. Schneider Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter Cancer Res. 63 2003 5538 5543
27. Q. Wang, and J.R. Halpert Combined three-dimensional quantitative structure-activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling Drug Metab. Dispos. 30 2002 86 95
28. R. Zhao, S. Babani, F. Gao, L. Liu, and I.D. Goldman The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate Clin. Cancer Res. 6 2000 3687 3695
29. W. Zheng, and A. Tropsha Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle J. Chem. Inf. Comput. Sci. 40 2000 185 194